IAA
SRPT icon

Ironsides Asset Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Ironsides Asset Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,605
Closed -$325K – 76
2024
Q3 		$325K Buy
+2,605
New +$360K 0.09% 58

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ironsides Asset Advisors's SRPT Position: Q4 2024 in Review

Ironsides Asset Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 2,605 shares — an estimated $325K sold.

Ironsides Asset Advisors first reported a position in SRPT in Q3 2024 and held it in 1 quarter. The position peaked at $325K in Q3 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

  • Ironsides Asset Advisors reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ironsides Asset Advisors sold 2,605 Sarepta Therapeutics shares in Q4 2024, an estimated $325K.
  • Ironsides Asset Advisors first reported a position in Sarepta Therapeutics in Q3 2024 and held it in 1 quarter.
  • Ironsides Asset Advisors's Sarepta Therapeutics position peaked at $325K in Q3 2024.
  • 464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Ironsides Asset Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.